Prognostic value of octamer binding transcription factor 4 for patients with solid tumors: A meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
16 Oct 2020
16 Oct 2020
Historique:
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
3
11
2020
Statut:
ppublish
Résumé
Octamer binding transcription factor 4 (Oct4) is critically important in the development and progression of cancer, and is considered a potential biomarker for tumor prognosis. However, the prognostic value of Oct4 in patients with solid tumors remains elusive. Herein, we conducted a meta-analysis to assess the prognostic value of Oct4 in patients with solid tumors. We conducted a literature search on PubMed, Embase, and Web of Science databases to retrieve comprehensive and eligible studies published until December 2019. The study was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS)/recurrence-free survival (RFS)/progress-free survival (PFS) were used to evaluate the prognostic value of Oct4 in patients with solid tumors via either random or fixed-effects models. In total, 36 studies with 5198 patients were included in the meta-analysis. Notably, elevated Oct4 expression was associated with worse OS (pooled HR: 2.02, 95% CI: 1.55-2.62, P < .001) and DFS/RFS/PFS (pooled HR: 2.34, 95% CI: 1.88-2.92, P < .001). This work demonstrated that patients with solid tumors show high expression of Oct4 which is linked to worse prognosis in patients with solid tumors including hepatocellular carcinoma (OS, DFS/RFS/PFS), esophageal squamous cell carcinoma (OS), gastric cancer (OS), cervical cancer (OS, DFS/RFS/PFS), and colorectal cancer (OS, DFS/RFS/PFS), this implicated Oct4 as a potential biomarker to predict the prognosis of tumors.
Sections du résumé
BACKGROUND
BACKGROUND
Octamer binding transcription factor 4 (Oct4) is critically important in the development and progression of cancer, and is considered a potential biomarker for tumor prognosis. However, the prognostic value of Oct4 in patients with solid tumors remains elusive. Herein, we conducted a meta-analysis to assess the prognostic value of Oct4 in patients with solid tumors.
METHODS
METHODS
We conducted a literature search on PubMed, Embase, and Web of Science databases to retrieve comprehensive and eligible studies published until December 2019. The study was conducted per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) and disease-free survival (DFS)/recurrence-free survival (RFS)/progress-free survival (PFS) were used to evaluate the prognostic value of Oct4 in patients with solid tumors via either random or fixed-effects models.
RESULTS
RESULTS
In total, 36 studies with 5198 patients were included in the meta-analysis. Notably, elevated Oct4 expression was associated with worse OS (pooled HR: 2.02, 95% CI: 1.55-2.62, P < .001) and DFS/RFS/PFS (pooled HR: 2.34, 95% CI: 1.88-2.92, P < .001).
CONCLUSION
CONCLUSIONS
This work demonstrated that patients with solid tumors show high expression of Oct4 which is linked to worse prognosis in patients with solid tumors including hepatocellular carcinoma (OS, DFS/RFS/PFS), esophageal squamous cell carcinoma (OS), gastric cancer (OS), cervical cancer (OS, DFS/RFS/PFS), and colorectal cancer (OS, DFS/RFS/PFS), this implicated Oct4 as a potential biomarker to predict the prognosis of tumors.
Identifiants
pubmed: 33080755
doi: 10.1097/MD.0000000000022804
pii: 00005792-202010160-00088
pmc: PMC7571959
doi:
Substances chimiques
Biomarkers, Tumor
0
Octamer Transcription Factor-3
0
POU5F1 protein, human
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22804Références
PLoS One. 2016 Dec 28;11(12):e0169129
pubmed: 28030635
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Radiol Oncol. 2016 Apr 23;50(2):188-96
pubmed: 27247551
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Med Oncol. 2014 Aug;31(8):130
pubmed: 25037576
J Histochem Cytochem. 2014 Jul;62(7):499-509
pubmed: 24710660
Annu Rev Pathol. 2016 May 23;11:47-76
pubmed: 27193450
J Surg Res. 2012 May 1;174(1):130-5
pubmed: 21227461
Surg Today. 2018 Jul;48(7):709-715
pubmed: 29488015
Future Oncol. 2018 Sep;14(22):2279-2291
pubmed: 29656661
PLoS One. 2015 Mar 27;10(3):e0118033
pubmed: 25816351
Neoplasma. 2016;63(2):288-98
pubmed: 26674131
J Transl Med. 2010 Oct 12;8:94
pubmed: 20937145
Oncol Rep. 2018 Aug;40(2):979-987
pubmed: 29901157
Cancer Res. 2008 Aug 15;68(16):6533-40
pubmed: 18701476
Ann Surg. 2011 Jun;253(6):1165-71
pubmed: 21394007
Lab Anim Res. 2011 Jun;27(2):147-52
pubmed: 21826175
Cancer Lett. 2013 Jun 1;333(1):56-65
pubmed: 23340171
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
J Surg Oncol. 2010 Dec 1;102(7):856-62
pubmed: 20818602
Oncogene. 2017 Jul 27;36(30):4253-4266
pubmed: 28319064
Clin Biochem. 2011 Jun;44(8-9):582-9
pubmed: 21376027
Am J Physiol Cell Physiol. 2015 Dec 1;309(11):C709-18
pubmed: 26447206
J Cancer. 2019 Jan 30;10(5):1313-1324
pubmed: 30854141
J Gastrointest Cancer. 2020 Mar;51(1):41-47
pubmed: 30628031
Pathol Res Pract. 2012 Sep 15;208(9):527-33
pubmed: 22824146
BMC Cancer. 2016 Mar 01;16:175
pubmed: 26931354
Biochim Biophys Acta Mol Basis Dis. 2020 Apr 1;1866(4):165432
pubmed: 30904611
BMC Cancer. 2015 Dec 26;15:1015
pubmed: 26706028
J Oral Pathol Med. 2016 Feb;45(2):89-95
pubmed: 26211876
Cancer Lett. 2013 Oct 28;340(1):113-23
pubmed: 23872274
Med Oncol. 2015 Jan;32(1):433
pubmed: 25491144
Cell. 1998 Oct 30;95(3):379-91
pubmed: 9814708
Lancet. 2018 Sep 22;392(10152):985
pubmed: 30264708
Biomed Res Int. 2018 Jul 12;2018:3424956
pubmed: 30112378
Trends Cell Biol. 2014 May;24(5):275-84
pubmed: 24370212
Zhonghua Kou Qiang Yi Xue Za Zhi. 2017 Jan 9;52(1):27-33
pubmed: 28072991
Artif Cells Nanomed Biotechnol. 2016 Dec;44(8):1818-1823
pubmed: 26631537
World J Gastroenterol. 2012 Feb 21;18(7):712-9
pubmed: 22363145
Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Aug;128(2):154-165
pubmed: 31078500
Front Oncol. 2018 Sep 19;8:386
pubmed: 30283733
Oncogene. 2012 Nov 22;31(47):4898-911
pubmed: 22286766
Expert Opin Drug Deliv. 2017 Aug;14(8):997-1008
pubmed: 27866420
PLoS One. 2012;7(11):e49693
pubmed: 23185410
Oncol Lett. 2013 Apr;5(4):1155-1162
pubmed: 23599755
Breast Cancer. 2018 Jul;25(4):447-455
pubmed: 29536377
Development. 2007 Feb;134(4):635-46
pubmed: 17215298
Zhongguo Fei Ai Za Zhi. 2013 Apr;16(4):197-202
pubmed: 23601300
Yonsei Med J. 2018 Jan;59(1):35-42
pubmed: 29214774
J Exp Clin Cancer Res. 2019 Nov 26;38(1):474
pubmed: 31771617
Tumour Biol. 2014 Jun;35(6):5339-45
pubmed: 24532469
Biomed Res Int. 2013;2013:648420
pubmed: 23984394
BMB Rep. 2017 Jun;50(6):285-298
pubmed: 28270302
Genomics. 1995 May 1;27(1):67-82
pubmed: 7665185
Breast Cancer Res. 2016 May 24;18(1):55
pubmed: 27220421
Stem Cell Rev Rep. 2018 Dec;14(6):769-784
pubmed: 30076557
Onco Targets Ther. 2018 Nov 06;11:7873-7881
pubmed: 30464534
Oncol Rep. 2013 Jan;29(1):155-60
pubmed: 23076549
Hum Pathol. 2016 May;51:1-8
pubmed: 27067776
Hepatology. 2010 Aug;52(2):528-39
pubmed: 20683952
Oncotarget. 2016 Nov 8;7(45):72767-72776
pubmed: 27611951
Med Oncol. 2012 Jun;29(2):829-34
pubmed: 21533858
Oncotarget. 2017 May 20;8(42):71933-71945
pubmed: 29069758
Mol Cancer. 2017 Feb 1;16(1):29
pubmed: 28148257
Epidemiol Rev. 1987;9:1-30
pubmed: 3678409
J Oral Pathol Med. 2014 Aug;43(7):492-8
pubmed: 24450601
Oncotarget. 2017 May 30;8(22):36305-36318
pubmed: 28422735